Ophthalmology

Autoimmune response drives vision loss in glaucoma

A research team from Massachusetts Eye and Ear and the Massachusetts Institute of Technology has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vis8/9/2018ion loss from glaucoma, the second leading cause of irreversible blindness in the world. The findings, published online in Nature Communications, suggest that high pressure in the eye leads to vision loss by
Gene Therapy

New gene therapy corrects a form of inherited macular degeneration in canine model

Researchers from the University of Pennsylvania have developed a gene therapy that successfully treats a form of macular degeneration in a canine model. The work sets the stage for translating the findings into a human therapy for an inherited disease that results in a progressive loss of central vision and which is currently untreatable. The study, published today in Proceedings of the National Academy of Sciences, was led by Karina
Biotechnology Cell Therapy Clinical Trials Infectious Diseases

Research with Zebrafish May Lead to Treatment for Blinding Disorders, Including Glaucoma

Jakub Famulski, an assistant professor of biology in the University of Kentucky College of Arts and Sciences, has received a grant for over $1.8 million from the National Institutes of Health to study the early formation of the anterior segment of the eye. The research has the potential to lead to more treatment options for patients with blinding disorders. The Research Project Grant (R01), "Comprehensive analysis of periocular mesenchyme composition, specification, and function during
Gene Therapy

Study advances gene therapy for glaucoma

While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains to control fluid pressure in the eye. Genes can't work until they enter a cell. Glaucoma, one of the most common blinding diseases, is caused by excess pressure inside the eye, usually due to a clog
Clinical Trials Ophthalmology rare diseases

Queen’s Researcher Explores Best Treatments for Glaucoma

Researchers at Queen’s University Belfast together with University of St Andrews and Aberdeen have found that the procedure used to remove cataracts is more successful than current standard treatments with laser in treating Primary Angle-Closure Glaucoma – a leading cause of irreversible blindness worldwide. Professor Azuara-Blanco at the Centre for Public Health at Queen’s led an international trial comparing two treatments for glaucoma – the standard treatment, or ‘laser iridotomy’,
Ophthalmology

Saving Sight In Glaucoma: Why The Brain May Hold The Key

What causes vision loss in glaucoma? There are two common answers that at first may seem disparate: the first is pressure, as in elevated ocular pressure, and the second is damage to the optic nerve, which is the structure that sends visual information to the brain. Both answers are correct. Glaucoma involves sensitivity to ocular pressure (not just elevated pressure) that is translated or transduced to stress that degrades the
Diabetes Neurology

Six Teams Seek To Identify Biological Factors That Influence Neural Regeneration

The National Institutes of Health will fund six projects to identify biological factors that affect neural regeneration in the retina. The projects are part of the National Eye Institute (NEI) Audacious Goals Initiative (AGI), a targeted effort to restore vision by regenerating neurons and their connections in the eye and visual system. These projects will receive a total of $12.4 million over three years, pending availability of funds. “Understanding factors